Printer Friendly
The Free Library
4,491,315 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Corporate Profile for Allergan Inc., dated Friday, Dec. 18., 1998.


--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.

Published Date:   Dec. 18, 1998

Company Name:     Allergan Inc.

Address:          2525 Dupont Drive
                  Irvine, Calif., 92612

Main Telephone
 Number:          714/246-4500

Internet Home
 Page Address
  (URL)           www.allergan.com

Chief Executive
 Officer:         David E.I. Pyott

Investor Relations
 Contact:         Jeffrey L. Edwards
 Business number: 714/246-6837

Public Relations
 Contact:         Ira Haskell
 Business number: 714/246-4515

Trading Symbol/
 Exchange:        NYSE:AGN

Industry:         Pharmaceutical


Company description: Allergan Inc., with headquarters in Irvine, Calif., is a technology-driven, global healthcare company, providing eye care and specialty

pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs and improve patients' lives.
COPYRIGHT 1998 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 18, 1998
Words:162
Previous Article:Energas raises $500,000 for a leasing fund.
Next Article:Corporate Profile for Rockwell International, dated Friday, Dec. 18, 1998.
Topics:



Related Articles
Allergan and Ligand form new research and development corporation to raise $100 million; File unit offering for $32.5 million.
Corporate Profile for Allergan Inc., dated March 20, 1998.
Allergan Reports First Quarter Results.
Allergan Announces Corporate Restructuring Plan; Special Charges of Approximately $103 Million for Work Force Reductions, Plant Consolidations and...
Allergan's ALOCRIL Receives FDA Marketing Approval for Treatment of Allergic Conjunctivitis.
Allergan In-Licenses Novel Compound for the Treatment of Ocular Allergy From Boehringer Ingelheim.
XOMA Meets First Allergan Milestone; Laboratory Studies Confirm Antibiotic Synergy.
Pyott's Voyage in Lilliput.(David E.I. Pyott, chief executive of Allergan)
BRIEFCASE PHILIP MORRIS CUTS SOME DISCOUNTING.(Business)
Botox marketing smooths wrinkles of trial publicity.(Up Front)

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles